Research programme: autoimmune disorders therapeutics - Delinia

Drug Profile

Research programme: autoimmune disorders therapeutics - Delinia

Alternative Names: DEL 106

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Delinia
  • Class Proteins
  • Mechanism of Action Interleukin-2 receptor agonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 26 Jan 2017 Celgene enters into an agreement to acquire Delinia
  • 26 Jan 2017 Celgene plans a clinical trial of DEL 106 for Autoimmune disorders
  • 19 Sep 2016 Preclinical trials in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top